| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 952 | 778 | 800 | 811 | 1,223 | 1,029 | 989 | 1,086 | 974 | 986 | 1,025 | 1,098 | 1,242 | 1,193 | 1,564 | 1,585 | 1,557 | 1,483 | 1,673 | 1,784 | 1,621 | 1,712 | 1,765 | 1,885 | 2,060 | 1,808 | 1,945 | 2,223 | 2,476 | 2,217 | 2,384 | 3,020 | 3,929 | 3,516 | 3,551 | 4,135 | 3,912 | 4,543 | 3,604 | 3,826 | 4,415 | 3,990 |
| Expenses | 653 | 606 | 727 | 615 | 740 | 719 | 706 | 762 | 738 | 735 | 786 | 836 | 937 | 886 | 982 | 1,160 | 1,137 | 1,029 | 1,174 | 1,307 | 1,247 | 1,284 | 1,363 | 1,459 | 1,476 | 1,427 | 1,515 | 1,733 | 1,911 | 1,783 | 1,894 | 2,624 | 2,820 | 2,741 | 2,769 | 3,051 | 3,013 | 2,813 | 2,905 | 3,070 | 3,339 | 3,193 |
| EBITDA | 300 | 172 | 73 | 196 | 483 | 309 | 283 | 324 | 236 | 250 | 239 | 262 | 306 | 307 | 582 | 425 | 420 | 454 | 499 | 477 | 373 | 428 | 402 | 427 | 584 | 380 | 430 | 489 | 565 | 434 | 490 | 396 | 1,109 | 775 | 782 | 1,084 | 900 | 1,730 | 699 | 756 | 1,077 | 797 |
| Operating Profit % | 21 % | 20 % | 6 % | 22 % | 21 % | 27 % | 25 % | 27 % | 20 % | 21 % | 19 % | 21 % | 20 % | 21 % | 26 % | 25 % | 26 % | 29 % | 25 % | 25 % | 20 % | 24 % | 22 % | 21 % | 20 % | 19 % | 18 % | 20 % | 21 % | 17 % | 18 % | 11 % | 25 % | 20 % | 18 % | 14 % | 22 % | 17 % | 18 % | 19 % | 23 % | 18 % |
| Depreciation | 59 | 59 | 61 | 64 | 65 | 66 | 68 | 70 | 73 | 99 | 94 | 97 | 95 | 99 | 112 | 117 | 120 | 124 | 132 | 144 | 152 | 167 | 178 | 186 | 184 | 195 | 202 | 206 | 212 | 218 | 231 | 301 | 364 | 358 | 389 | 415 | 407 | 405 | 420 | 425 | 436 | 455 |
| Interest | 0 | 4 | 3 | 2 | 21 | 6 | 7 | 9 | 5 | 16 | 14 | 15 | 17 | 18 | 19 | 19 | 16 | 17 | 14 | 18 | 17 | 13 | 7 | 5 | 34 | 20 | 23 | 15 | 11 | 20 | 30 | 120 | 249 | 233 | 248 | 267 | 227 | 236 | 226 | 223 | 212 | 277 |
| Profit Before Tax | 249 | 165 | 20 | 141 | 409 | 238 | 208 | 245 | 159 | 135 | 132 | 150 | 193 | 190 | 451 | 289 | 284 | 313 | 354 | 315 | 204 | 249 | 218 | 236 | 366 | 166 | 206 | 269 | 343 | 197 | 229 | -26 | 497 | 184 | 214 | 808 | 319 | 1,146 | 98 | 156 | 487 | 97 |
| Tax | 32 | 34 | 18 | 19 | 55 | 55 | 42 | 54 | 10 | 38 | 43 | 36 | 41 | 52 | 73 | 46 | 41 | 85 | 100 | 85 | 45 | 81 | 22 | 49 | 69 | 57 | 46 | 49 | 59 | 30 | 147 | -5 | 82 | 35 | 42 | 55 | 96 | 284 | 71 | 75 | 27 | 8 |
| Net Profit | 217 | 131 | 2 | 122 | 354 | 182 | 167 | 191 | 148 | 98 | 89 | 114 | 153 | 138 | 378 | 243 | 243 | 228 | 254 | 230 | 159 | 168 | 195 | 187 | 296 | 108 | 160 | 220 | 284 | 167 | 82 | -21 | 415 | 149 | 173 | 753 | 223 | 862 | 27 | 81 | 459 | 89 |
| EPS in ₹ | 10.08 | 6.31 | -0.54 | 5.30 | 16.97 | 8.49 | 7.48 | 8.72 | 6.49 | 1.38 | 1.17 | 1.56 | 2.21 | 1.02 | 3.00 | 3.67 | 3.61 | 1.74 | 1.82 | 1.71 | 1.04 | 1.26 | 1.39 | 1.42 | 2.13 | 0.71 | 1.16 | 1.57 | 2.00 | 1.21 | 0.39 | -0.35 | 2.62 | 0.85 | 1.05 | 5.52 | 1.13 | 5.51 | -0.13 | 0.21 | 2.88 | 0.26 |
Biocon
Biocon
349.00
+1.20
(0.35%)
Key Fundamentals
Market Cap
46,499.60 Cr
EPS
8.46
PE Ratio
131.04
Dividend Yield
0.13 %
Industry
Healthcare 52 Week High
406.00
52 Week Low
291.00
PB Ratio
1.78
Debt to Equity
0.84
Sector
Pharmaceuticals Analyst Rating and Forecast
- By Refinitiv from16 analysts
Actual
Company News
View All News
Biocon's subsidiary Biocon Pharma, along with Carnegie Pharmaceuticals, has received tentative approval from the US Food and Drug Administration for Rifaximin tablets in 550 mg strength. This regulatory milestone allows the companies to move forward with their pharmaceutical product in the US market.
Biocon Limited's Board of Directors approved the early full redemption of 107,000 unlisted, secured, rated, redeemable Non-Convertible Debentures worth Rs 1,070 crores. The NCDs had a face value of Rs 1 lakh each and were originally issued on February 21, 2023. The company has completed payment to debenture holders and the debenture trustee for the early redemption. The Board meeting was held on October 1, 2025, lasting from 6:30 PM to 6:48 PM IST.
Biocon Biologics Receives U.S. Approval Date for Denosumab Biosimilars Bosaya™ and Aukelso™
7 days ago
7 days agoBiocon Biologics has received a U.S. approval date for its denosumab biosimilars, Bosaya™ and Aukelso™. These are biosimilar versions of denosumab, targeting the U.S. pharmaceutical market.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,631.60 | #1 3,96,634.10 | 34.59 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 52.19 | |
6,120.50 | 1,62,055.30 | 67.06 | 9,712.00 | 18.67 | 2,191 | 26.74 | 56.39 | |
1,494.60 | 1,22,237.40 | 22.67 | 28,409.50 | 7.12 | 5,291 | 9.88 | 38.43 | |
3,569.00 | 1,19,704.80 | 59.08 | 11,539.40 | 6.99 | 1,911 | 19.91 | 49.24 | |
1,234.50 | 1,04,201.50 | #1 18.34 | 33,741.20 | 16.73 | 5,725 | 1.26 | 39.35 | |
2,454.90 | 1,02,393.00 | 53.53 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 39.95 | |
985.95 | 99,405.90 | 21.46 | 23,511.00 | 18.55 | 4,615 | 2.60 | 42.63 | |
1,905.60 | 87,916.10 | 23.93 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 40.58 | |
5,493.50 | 65,665.10 | 28.86 | 13,458.30 | 3.70 | 2,216 | 21.39 | 58.27 | |
29,925.00 | 63,376.00 | 43.95 | 6,684.70 | 9.64 | 1,414 | 11.55 | 38.74 |
Growth Rate
Revenue Growth
5.43 %
Net Income Growth
10.14 %
Cash Flow Change
37.49 %
ROE
0.58 %
ROCE
1.95 %
EBITDA Margin (Avg.)
-0.38 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,444 | 18,522 | 20,394 | 52,043 | 56,071 | 58,797 |
| Fixed Assets | 1,630 | 1,749 | 3,626 | 3,700 | 4,471 | 5,971 | 6,364 | 6,569 | 29,468 | 30,644 | 31,963 |
| Current Assets | 2,563 | 3,971 | 4,048 | 4,149 | 4,889 | 5,325 | 7,600 | 8,382 | 12,334 | 15,179 | 16,286 |
| Capital Work in Progress | 1,677 | 2,240 | 839 | 1,303 | 1,899 | 2,196 | 2,800 | 4,110 | 7,317 | 7,993 | 8,508 |
| Investments | 230 | 901 | 1,253 | 675 | 1,012 | 966 | 1,952 | 1,588 | 2,069 | 1,000 | 1,127 |
| Other Assets | 2,839 | 3,569 | 3,676 | 4,312 | 4,811 | 5,311 | 7,406 | 8,127 | 13,189 | 16,434 | 17,199 |
| Total Liabilities | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,444 | 18,522 | 20,394 | 52,043 | 56,071 | 58,797 |
| Current Liabilities | 1,555 | 1,666 | 1,678 | 2,141 | 3,039 | 4,008 | 4,210 | 3,828 | 8,511 | 15,359 | 14,334 |
| Non Current Liabilities | 1,378 | 2,493 | 2,502 | 2,200 | 2,447 | 3,053 | 5,805 | 7,096 | 21,043 | 15,437 | 16,751 |
| Total Equity | 3,443 | 4,300 | 5,214 | 5,649 | 6,707 | 7,383 | 8,508 | 9,470 | 22,489 | 25,275 | 27,713 |
| Reserve & Surplus | 3,171 | 3,992 | 4,738 | 4,881 | 5,798 | 6,106 | 7,027 | 7,832 | 17,267 | 19,183 | 21,044 |
| Share Capital | 100 | 100 | 100 | 300 | 300 | 600 | 600 | 600 | 600 | 600 | 600 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -94 | 300 | -47 | -261 | 210 | 165 | 72 | -243 | 641 | -380 | 2,004 |
| Investing Activities | -491 | -1,138 | -510 | -684 | -703 | -1,505 | -3,651 | -1,662 | -14,260 | -1,002 | -203 |
| Operating Activities | 211 | 371 | 640 | 662 | 1,155 | 1,283 | 1,160 | 1,177 | 1,853 | 2,954 | 4,061 |
| Financing Activities | 186 | 1,068 | -178 | -240 | -242 | 388 | 2,564 | 242 | 13,049 | -2,333 | -1,854 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 60.67 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 54.45 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 7.96 % | 6.55 % | 5.63 % | 5.90 % | 5.93 % | 5.66 % | 5.66 % | 6.04 % |
| DIIs | 6.65 % | 6.89 % | 6.87 % | 6.83 % | 7.79 % | 7.30 % | 7.76 % | 8.63 % | 11.90 % | 12.56 % | 14.08 % | 14.51 % | 13.68 % | 14.30 % | 14.44 % | 15.37 % | 15.72 % | 22.82 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 10.89 % | 11.03 % | 11.49 % | 11.37 % | 10.87 % | 10.72 % | 12.07 % | 12.46 % | 13.21 % | 13.34 % | 13.61 % | 14.47 % | 15.53 % | 14.63 % | 14.57 % | 14.07 % | 13.63 % | 12.58 % |
| Others | 21.79 % | 21.44 % | 21.00 % | 21.16 % | 20.70 % | 21.35 % | 19.54 % | 18.27 % | 14.26 % | 13.46 % | 3.70 % | 3.83 % | 4.52 % | 4.53 % | 4.42 % | 4.27 % | 4.34 % | 4.10 % |
| No of Share Holders | 0 | 3,11,349 | 3,38,815 | 3,63,447 | 3,64,502 | 3,47,911 | 3,41,016 | 3,69,816 | 4,11,086 | 4,12,441 | 4,15,046 | 4,34,339 | 4,70,261 | 4,43,513 | 4,39,503 | 4,27,705 | 4,24,297 | 4,30,217 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3 | 1 | 1 | 0.00 | 0.00 | 0.5 | 1.5 | 0.5 | 0.5 |
| Dividend Yield (%) | 0.00 | 1.01 | 0.33 | 0.37 | 0.00 | 0.00 | 0.25 | 0.57 | 0.15 | 0.14 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 13 Jun 2019 |  Bonus | 1:1 | 12 Jun 2019 | 271.45 | 257.90 |
| 01 Jul 2022 |  Dividend | ₹ 0.50 /share | 30 Jun 2022 | 382.30 | 308.40 |
| 07 Jul 2023 | Dividend | ₹ 1.50 /share | 07 Jul 2023 | 240.45 | 259.50 |
| 05 Jul 2024 | Dividend | ₹ 0.50 /share | 05 Jul 2024 | 311.90 | 361.10 |
| 09 Aug 2024 |  Annual General Meeting | NA | 09 Aug 2024 | 311.90 | 339.20 |
| 30 Oct 2024 |  Quarterly Result Announcement | NA | 30 Oct 2024 | 370.65 | 326.85 |
| 30 Jan 2025 | Quarterly Result Announcement | NA | 30 Jan 2025 | 372.95 | 355.70 |
| 08 May 2025 | Quarterly Result Announcement | NA | 08 May 2025 | 339.10 | 346.50 |
| 04 Jul 2025 | Dividend | ₹ 0.50 /share | 04 Jul 2025 | 346.50 | 374.40 |
| 07 Aug 2025 | Quarterly Result Announcement | NA | 07 Aug 2025 | 372.05 | 360.60 |
| 08 Aug 2025 | Annual General Meeting | NA | 08 Aug 2025 | 346.50 | 364.20 |
Announcements
Notification To Stock Exchanges1 day ago
1 day agoBoard Meeting Intimation for Intimation Of The Date Of Board Meeting2 days ago
2 days agoBoard Meeting Outcome for Early Redemption Of Ncds7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release7 days ago
7 days agoBoard Meeting Intimation for Proposed Early Redemption Of Unlisted Secured Rated Redeemable Non-Convertible Debentures (Ncds).9 days ago
9 days agoClosure of Trading WindowSep 26, 2025
Sep 26, 2025Announcement Under Regulation 30 - Receipt Of Show Cause NoticeSep 25, 2025
Sep 25, 2025Buyback Of Commercial PaperSep 19, 2025
Sep 19, 2025Intimation Of Record Date For Buy Back Of Listed Commercial Paper Issued By The CompanySep 17, 2025
Sep 17, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 17, 2025
Sep 17, 2025Letters To Shareholders Under 100 Days Campaign - Saksham NiveshakSep 13, 2025
Sep 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 12, 2025
Sep 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 11, 2025
Sep 11, 2025Email Communication To Shareholders Under 100 Days Campaign - Saksham NiveshakSep 10, 2025
Sep 10, 2025Announcement under Regulation 30 (LODR)-Change in ManagementSep 09, 2025
Sep 09, 2025Board Meeting Outcome for Outcome Of Board MeetingSep 09, 2025
Sep 09, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 09, 2025
Sep 09, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 05, 2025
Sep 05, 2025Company StatementSep 04, 2025
Sep 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 02, 2025
Sep 02, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 29, 2025
Aug 29, 2025Notification To Stock ExchangesAug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 20, 2025
Aug 20, 2025Transcript Of Earnings Call Q1 FY26Aug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 14, 2025
Aug 14, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 09, 2025
Aug 09, 2025ChairpersonS Speech At The 47Th Annual General Meeting Of The CompanyAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 08, 2025
Aug 08, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-AcquisitionAug 07, 2025
Aug 07, 2025Outcome Of Board Meeting - AcquisitionAug 07, 2025
Aug 07, 2025Board Meeting Outcome for Financial Results For June 30 2025Aug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 07, 2025
Aug 07, 2025Financial Results For The Quarter Ended June 30 2025Aug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 23, 2025
Jul 23, 2025Company StatementJul 23, 2025
Jul 23, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 18, 2025
Jul 18, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 17, 2025
Jul 17, 2025Reg. 34 (1) Annual Report.Jul 17, 2025
Jul 17, 2025 47Th Annual General Meeting For Financial Year 2024-25 To Be Held On Friday August 08 2025Jul 17, 2025
Jul 17, 2025Press ReleaseJul 15, 2025
Jul 15, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2025
Jul 10, 2025Certificate Pursuant To SEBI Master Circular No. SEBI/HO/DDHS/Pod1/P/CIR/2024/54
Dated May 22 2024.Jul 10, 2025
Jul 10, 2025Outcome Of Board Meeting - Appointment Of Interim Company Secretary And Compliance OfficerJul 09, 2025
Jul 09, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 09, 2025
Jul 09, 2025Mutual Fund Holdings
SBI Contra Direct Plan-Growth 
Kotak Large & Midcap Fund Direct-Growth 
Nippon India Multi Cap Fund Direct-Growth 
Franklin India Mid Cap Fund Direct-Growth 
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth 
HSBC Midcap Fund Direct-Growth 
Invesco India Arbitrage Fund Direct-Growth 
Axis Midcap Direct Plan-Growth 
Mirae Asset Midcap Fund Direct - Growth 
Tata Arbitrage Fund Direct - Growth 
Bandhan Large & Mid Cap Fund Direct-Growth Technical Indicators
RSI(14)
Neutral 43.25
ATR(14)
Less Volatile 7.99
STOCH(9,6)
Neutral 28.54
STOCH RSI(14)
Neutral 48.95
MACD(12,26)
Bearish -0.75
ADX(14)
Weak Trend 19.76
UO(9)
Bearish 41.11
ROC(12)
Downtrend And Accelerating -5.59
WillR(14)
Neutral -70.79
About Biocon
Biocon Limited is India's largest fully-integrated biopharmaceutical company, focusing on biotechnology products and research services. Founded in 1978, Biocon specializes in treating diabetes, cancer, and autoimmune diseases. The company develops and commercializes novel biologics, biosimilars, complex small molecule APIs, and generic formulations for global markets. Biocon's product portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, and oncology treatments. The company operates manufacturing facilities in Bangalore, Hyderabad, and Visakhapatnam, utilizing various technology platforms such as microbial fermentation, chromatographic purification, chemical synthesis, and peptide synthesis. Biocon has expanded its global presence through strategic partnerships and has launched several biosimilar and generic products in international markets, including the United States, Europe, and emerging economies.
Listing Date
07 Apr, 2004(21 Years,
1 days)
Website
Chairperson NameKiran Mazumdar Shaw
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
